CoChat

Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults

Open access

Published version of a preprint

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Background: Irritable bowel syndrome (IBS) with diarrhoea (IBS-D) is a common and chronic condition that can significantly impair quality of life. The emergence of new drugs for IBS-D has been slow and there is a need for new treatments, including drug-free treatments, which are easy to use and suitable for different patient groups. Currently available drug-free treatments include Enterosgel®, an intestinal adsorbent approved for use in IBS-D and acute diarrhoea and available over-the-counter in the UK and 30 countries worldwide. The aim of this randomised, double-blind, placebo-controlled, multi-centre study is to test the efficacy and safety of Enterosgel® compared to placebo in symptomatic treatment in IBS-D. Methods/design: We will recruit 430 participants with IBS-D from approximately 30 primary and secondary care sites in England. Participants meeting the required abdominal pain and stool consistency criteria over a 2-week screening period will be randomly allocated to receive blinded treatment (Enterosgel® or placebo) for 8 weeks. This will be followed by an 8-week open-label treatment phase with Enterosgel®. Participants will be allowed to adjust their daily dosage during both phases based on their symptoms. Participants will then return to standard care and those who responded to treatment will receive a follow-up call 8 weeks later. Co-medication with loperamide will be permitted and use recorded. The primary outcome measure is the percentage of participants defined as responders for abdominal pain and stool consistency during at least 4 weeks in the 8-week blinded phase. Secondary outcome measures include stool frequency, stool consistency, abdominal pain, bloating, urgency, adequate relief, questionnaire scores and rescue medication use. Exploratory outcomes will be assessed in subsets of participants including qualitative and quantitative data on faecal microorganisms and biomarkers and gut-related measurements from magnetic resonance imaging data. Discussion: This is the first large scale randomised controlled trial investigating Enterosgel® in IBS-D. A study design with blinded phase followed by an open-label phase was chosen to encourage participation and study completion. Demonstrating that Enterosgel® is effective and safe in IBS-D could encourage adoption by patients and healthcare professionals and foster future clinical trials assessing its use in related conditions. Trial registration: ISRCTN17149988 . Prospectively registered on 14 November 2017.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13063-020-4069-x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design
Fig. 1 Study designCC BY · PubMed Central
Fig. 2 SPIRIT figure
Fig. 2 SPIRIT figureCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 5

  1. World Gastroenterology Organisation. Global Guidelines. Updated September 2015. Irritable bowel syndrome: a global perspective. 2015. http://www.worldgastroenterology.org/guidelines/global-guidelines/irritable-bowel-syndrome-ibs. Accessed 13 Mar 2019.
  2. International Foundation for Functional Gastrointestinal Disorders. IBS in the real world survey. Summary findings. 2002. https://www.iffgd.org/images/pdfs/IBSRealWorld.pdf. Accessed 13 Mar 2019.
  3. Leonard AJD-LM, Allen A. Pepsin damage in rat stomach in vivo: effect of smectite and dimethyl prostaglandin E2. Gastroenterology. 1993;104:A132.
  4. Tkachenko EIAE, Skazyvaeva EV, Ivanov SV, Pushklna AV, Lapinskii IV. Efficiency and safety of Enterosgel (polymethylsiloxane polyhydrate) in the treatment of irritable bowel syndrome. Minerva Gastroenterol Dietol. 2015;61(N2):1–5.
  5. Pavlov AIFZV. Tactics of management of diarrhoea of non-infectious genesis in hospital (in Russian). Military Med J. 2018;6:49–54.

Cited by

See all 14

Metadata

Authors
Kemppinen, A., Howell, C., Allgar, V., Dodd, M., Gregson, J., Knowles, C., McLaughlin, J., Pandya, P., Whorwell, P., Markaryan, E., & Yiannakou, Y.
Affiliations
  • Enteromed (United Kingdom) (GB)
  • University of York (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • Queen Mary University of London (GB)
  • Salford Royal NHS Foundation Trust (GB)
  • University of Manchester (GB)
  • County Durham and Darlington NHS Foundation Trust (GB)
Corresponding author
Kemppinen, Anu
Venue
Trials
Published
2020-01-30
Volume
21
Issue
1
Pages
122-122
ISSN
1745-6215 (ISSN-L)
OpenAlex
W3004297104
Cited by
14
References
28
Citations by year
2026: 1 · 2025: 3 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 1
FWCI
2.17
Type
journal article
Language
en
Open access
Licence
Locations
  • Trials (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • PEARL (University of Plymouth) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion, other-oa)
Funders
Bioline Products s.r.o (n/a)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
  • Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
Keywords
irritable bowel syndrome with diarrhea, Enterosgel, drug-free treatment, abdominal pain, stool consistency, stool frequency, bloating, gut microbiota biomarkers, treatment efficacy and safety
MeSH terms
Adult, Diarrhea, Double-Blind Method, Drug Carriers, Female, Gastrointestinal Agents, Humans, Intestinal Absorption, Male, Surveys and Questionnaires, Silicones, Multicenter Studies as Topic, Abdominal Pain, Randomized Controlled Trials as Topic, Sorption Detoxification, Outcome Assessment, Health Care, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. https://app.cochat.ai/papers/10.1186/s13063-020-4069-x
The paper
Kemppinen, A., Howell, C., Allgar, V., Dodd, M., Gregson, J., Knowles, C., McLaughlin, J., Pandya, P., Whorwell, P., Markaryan, E., & Yiannakou, Y. (2020). Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Trials. https://doi.org/10.1186/s13063-020-4069-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.